6533b870fe1ef96bd12cf321

RESEARCH PRODUCT

Predictors of residual T1 high grade on re-transurethral resection in a large multi-institutional cohort of patients with primary T1 high-grade/grade 3 bladder cancer

Daniela TerraccianoSavino M. Di StasiSisto PerdonàEttore De BerardinisBattaglia MGiuseppe MorgiaPierluigi BoveFrancesco A. MistrettaGiuseppe Di LorenzoRoberto La RoccaRodolfo HurleVerze PaoloMatteo MutoRiccardo AutorinoMihai Dorin VartolomeiGiorgio GuazzoniRocco DamianoSerretta VincenzoGian Maria BusettoRiccardo SchiavinaMatteo FerroFrancesco CantielloMarco BorghesiGennaro MusiNicolae CrisanGiuseppe LucarelliOttavio De CobelliGiovanni GrimaldiVincenzo MironeCarlo BuonerbaGilberto L. AlmeidaDeliu Victor MateiGiorgio Ivan RussoAbdal Rahman Abu FarhanEstevão Lima

subject

Bladder cancer; High-grade; Neutrophil-to-lymphocytes ratio; Re-transurethral resection; Oncologymedicine.medical_specialty030232 urology & nephrologyUrologyOverweightResidualLogistic regressionSettore MED/24 - Urologia03 medical and health sciences0302 clinical medicineRe-transurethral resectionHigh-grademedicinehigh-grade2. Zero hungerBladder cancerScience & Technologybusiness.industryCarcinoma in situBladder cancerCancerre-transurethral resectionmedicine.disease3. Good healthre-transurethral resection.Oncology030220 oncology & carcinogenesisConcomitantCohortbladder cancermedicine.symptomNeutrophil-to-lymphocytes ratiobusinessneutrophil-to-lymphocytes ratioResearch Paper

description

The aim of this multi-institutional study was to identify predictors of residual high-grade (HG) disease at re-transurethral resection (reTUR) in a large cohort of primary T1 HG/Grade 3 (G3) bladder cancer patients. A total of 1155 patients with primary T1 HG/G3 bladder cancer from 13 academic institutions that underwent a reTUR within 6 weeks after first TUR were evaluated. Logistic regression analysis was performed to assess the association of predictive factors with residual HG at reTUR. Residual HG cancer was found in 288 (24.9%) of patients at reTUR. Patients presenting residual HG cancer were more likely to have carcinoma in situ (CIS) at first resection (p=25 kg/m2. On multivariable analysis, independent predictors for HG residual disease at reTUR were tumor size >3cm (OR = 1.37; 95% CI: 1.02-1.84, p=0.03), concomitant CIS (OR 1.92; 95% CI: 1.32-2.78, p=0.001), being overweight (OR= 2.08; 95% CI: 1.44-3.01, p=25 kg/m2.

yearjournalcountryeditionlanguage
2018-01-01
10.7150/jca.26129http://hdl.handle.net/11588/738496